Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Crucell N.V. (CRXL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (29)	10/5/2001 5:53:35 AM
From: nigel bates	Respond to of 560

LEIDEN, Netherlands, Oct. 5 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL - news; Euronext Amsterdam: CRXL), today announced that it has appointed renowned immunologist Ada Kruisbeek as Senior Vice President Head of Oncology and Inflammatory Diseases. Prof. Kruisbeek will lead Crucell's antibody research. Prof. Kruisbeek worked for the past 10 years at the Netherlands Cancer Institute in Amsterdam, first as chairman of the department of Immunology, and more recently as laboratory research coordinator for all research divisions. Between 1978 and 1991 she worked at the National Institute of Health (NIH), Bethesda, MD (USA) in various senior positions. She currently serves on the advisory board of several national and international scientific agencies and research institutes. She is a Professor of molecular immunology at the Free University of Amsterdam. ``A major hurdle in the development of antibodies has been the identification of disease associated target molecules. Through these molecules antibodies specifically attack diseased cells and tissues, without harming healthy cells and tissues. Crucell's unique MAbstract technology takes this hurdle and allows for the rational design, development and evaluation of monoclonal antibody therapeutics,'' said Prof. Kruisbeek. Currently, Crucell has five fully human antibodies in various stages of pre-clinical development for the treatment of colon cancer, breast cancer, anti-angiogenesis, leukemia and inflammation. Additional programs have been launched in oncology, diabetes and cardiovascular diseases. In August 2001, the company entered into an agreement with Centocor, a Johnson & Johnson company, for the development and commercialization of its CD46-specific human antibodies for the treatment of cancer. Commenting on the appointment, Crucell CSO Ton Logtenberg said: ``We are extremely fortunate to have attracted a world-renowned Immunologist to head our Oncology and Inflammatory Disease departments. Professor Kruisbeek's outstanding track record and our proprietary technologies increase the capacity of Crucell to create innovative drugs.'' About Crucell Crucell, a leading biotechnology company, discovers and develops biopharmaceutical products that utilize the immune system to combat disease. Crucell's human technology platforms, MAbstract(TM) and PER.C6(TM), are applicable for discovery and development of antibody and vaccine products. Crucell's MAbstract(TM) discovery and development programs are focused on human antibody-based therapeutics for treatment of cancer and inflammatory diseases. Crucell's vaccine programs are focused on the prevention and treatment of influenza and other infectious diseases. Crucell enters into licensing or co-development agreements for its in-house products, or starts new target discovery and product development programs with partners. Crucell's PER.C6(TM) fully human production cell line technologies are made available under license agreements for antibodies, proteins, vaccines and vector technology applications. Crucell has currently signed 18 PER.C6(TM) agreements with major pharmaceutical and biotechnology companies. Crucell has a listing on NASDAQ and Euronext, and has raised EUR 144 million in its October 2000 IPO. Crucell currently employs approximately 140 people in its facilities in Leiden and Utrecht. This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. See our Registration Statement, as filed on Form F-1 with the U.S. Securities and Exchange Commission on October 26, 2000, (the ``Registration Statement'') and the section of the Registration Statement entitled ``Risk Factors.'' SOURCE: Crucell N.V.